FDA approves Triptodur for central precocious puberty

Debiopharm Group (Lausanne, Switzerland) and Arbor Pharmaceuticals LLC (Atlanta, Ga.) said FDA approved Triptodur triptorelin to treat pediatric patients ages ≥2 with central precocious puberty. The companies plan to launch the product in 4Q17...